This content is from: Premium Viking Emerges Relatively Unscathed From a Bleak 2022 The Tiger Cub’s small year-long loss was a moral victory for the firm. By Stephen Taub January 12, 2023
This content is from: Premium These Biopharma Funds Made a Comeback Last Year While some funds posted huge losses in 2022, several others managed to turn sharp losses into profitability. By Stephen Taub January 19, 2023
This content is from: Premium Dorsal Escapes 2022 With Just a Scratch The firm’s tech-heavy main fund, which has never suffered a large annual loss, was nearly profitable last year. By Stephen Taub January 18, 2023
This content is from: Premium It Was a Tough Year to Be a Tiger Tiger Global, Lone Pine, Maverick, and other descendants of Tiger Management suffered huge losses in 2022. By Stephen Taub January 11, 2023
This content is from: Premium Macro Takes a Beating in November Haidar and Bridgewater both suffered large losses. By Stephen Taub December 06, 2022
This content is from: Portfolio Is It Time To Buy Growth Stocks Again？ After the sector’s losses last year, Polen Capital’s Rayna Lesser Hannaway says the job is now to separate the winners from the losers. By Hannah Zhang January 13, 2023
